Research Topics
| Joan L WalkerSummaryAffiliation: University of Oklahoma Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Management of atypical and low-grade cervical cytologyCamille A Falkner
Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Cancer J 9:377-81. 2003..with cytology in the screening of women for cervical neoplasia adds a new dilemma to patient management: What should we do with women who are positive for high-risk human papillomavirus DNA but have negative cervical cytologic results?..- Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissectionRam Eitan
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 93:260-2. 2004..Consideration should be given to evaluate this area during staging laparotomy or laparoscopy. The role of routine bilateral infrarenal aortic nodal dissection needs further evaluation... - Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?Scott A Kamelle
Oklahoma Health Sciences Center, USA
Gynecol Oncol 94:249-55. 2004..To evaluate how the independent predictors of recurrence for stage IB2 cervical cancers treated with up-front radical hysterectomy apply to established risk models... 
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 StudyJoan L Walker
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
J Clin Oncol 30:695-700. 2012..The primary objective was to establish noninferiority of laparoscopy compared with laparotomy for recurrence after surgical staging of uterine cancer...- HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancerRosemary E Zuna
Department of Pathology, University of Oklahoma Health Sciences Center, 940 SL Young Blvd, Oklahoma City, Oklahoma, 73104 5042, USA
Infect Agent Cancer 6:19. 2011..abstract:.. 
A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group studyJoan L Walker
Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
Gynecol Oncol 112:78-84. 2009..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with extended field irradiation in women with cervical cancer metastatic to the para-aortic nodes...- Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS)Joan L Walker
Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA
Am J Obstet Gynecol 195:341-8. 2006..Using data from the ASCUS-LSIL Triage Study (ALTS) to inform clinical management, we calculated the absolute risk for developing CIN3 within 2 years of referral to an enrollment colposcopy... - Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group StudyJoan L Walker
Department of Obstetrics and Gynecology, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190, USA
Gynecol Oncol 100:27-32. 2006..To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy... - Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2Joan L Walker
University of Oklahoma, Oklahoma City, OK 73190, USA
J Clin Oncol 27:5331-6. 2009..The objective was to compare laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer... - Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysisLisa M Landrum
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Gynecol Oncol 112:337-41. 2009..The objective of this study is to evaluate overall survival (OS) and progression-free survival (PFS) in patients with advanced EC compared to a cohort of patients with OC matched for age and residual disease... - A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a GynecologicNatalie Gould
Division of Gynecologic Oncology, Women s Cancer Center of Nevada, Las Vegas, NV 89169, USA
Gynecol Oncol 127:506-10. 2012.... - A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic OncolNatalie Gould
Division of Gynecologic Oncology, Women s Cancer Center of Nevada, Las Vegas, NV 89169, USA
Gynecol Oncol 125:54-8. 2012.... - Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion ratesLisa M Landrum
Section of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P O Box 26901, WP 2410, Oklahoma City, OK 73190, USA
Gynecol Oncol 108:342-7. 2008..The purpose of this study was to review the completion rate of patients receiving i.p. chemotherapy as first line treatment at a single institution and determine what factors prohibit completion of therapy... - Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?Kathleen N Moore
University of Oklahoma Health Sciences Center, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73103, USA
Gynecol Oncol 110:133-9. 2008..Optimal management for very elderly women (>80) is unclear. This study sought to review the experience with treating ovarian cancer in this population... - Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomesKathleen N Moore
University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Boulevard, Oklahoma City, OK, USA
Gynecol Oncol 108:466-71. 2008..To examine surgico-pathologic outcomes following extraperitoneal para-aortic lymph node dissection (EPLND) via pfannenstiel compared to paramedian incision prior to radiation in patients with cervical cancer... - Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiationLisa M Landrum
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, PO Box 26901, Williams Pavilion 2410, Oklahoma City, OK 73190, USA
Gynecol Oncol 108:584-90. 2008.... - Preoperative predictors of positive margins after loop electrosurgical excisional procedure-ConeTodd D Tillmanns
Department of Obstetrics and Gynecology, University of Tennessee at Memphis, 854 Jefferson Ave, Room E 102, Memphis, TN 38163, USA
Gynecol Oncol 100:379-84. 2006..A LEEP-Cone may not be necessary for all patients with traditional cone indications. This study defines populations where a single pass technique with the LEEP is appropriate... - Carcinosarcoma of the ovary-a case seriesTeresa L Rutledge
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Gynecol Oncol 100:128-32. 2006..To evaluate our experience with ovarian carcinosarcoma and identify prognostic factors... - Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern eraLisa M Landrum
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Oklahoma University Health Sciences Center, PO Box 26901, WP2410, Oklahoma City, OK 73190, USA
Gynecol Oncol 106:521-5. 2007..The purpose of this study is to reassess these risk groups in patients treated in an era of contemporary management... - Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group studyD Scott McMeekin
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
Gynecol Oncol 112:134-41. 2009..To determine the maximum tolerated dose (MTD) and feasibility of weekly cisplatin and paclitaxel chemotherapy administered concurrently with whole abdominal radiation therapy (WART) in women with high-risk endometrial cancer... - Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancerLisa M Landrum
University of Oklahoma Health Sciences Center, Section of Gynecology Oncology, Oklahoma City, OK 73190, USA
Gynecol Oncol 122:527-31. 2011..CONCLUSIONS.: Although only 52% of patients were able to complete 6 cycles of cisplatin-based IP chemotherapy, significant reductions in cisplatin-related metabolic toxicity and catheter-related complications were noted... - Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology GroupPaul A DiSilvestro
Program in Womens Oncology, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, and Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City 73190, USA
Gynecol Oncol 103:1038-42. 2006..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cervical cancer... - Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?Kathleen N Moore
Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
Cancer 115:1472-80. 2009..In the current study, chemotherapy-related toxicity data were evaluated between patients aged > or = 80 years and those aged < 80 years... - Role of laparoscopic surgery in the management of endometrial cancerMeaghan Tenney
Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
J Natl Compr Canc Netw 7:559-67. 2009..This article documents how laparoscopic surgery satisfies the needs of individual patients and surgeons treating this disease... - Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trialFrederick B Stehman
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Am J Obstet Gynecol 197:503.e1-6. 2007.... - Tubal ligation frequency in Oklahoma women with cervical cancerCara A Mathews
Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Gynecol Oncol 127:278-82. 2012..Infrequent Pap screening is an important risk factor for cervical cancer. We studied the association between contraceptive methods, screening frequency, and cancer... - Pathologic findings and outcomes for octogenarians presenting with uterine malignancyKathleen N Moore
University of Oklahoma Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73103, USA
Gynecol Oncol 106:572-8. 2007..We evaluated prognostic, demographic and outcome data for patients>80 years old with uterine cancer (UC)... - Impact of individual physicians on enrollment of patients into clinical trialsRobert S Mannel
Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, U.S.A
Am J Clin Oncol 26:171-3. 2003..This study shows that availability of patients, patient variances, support staff, and institutional commitment are secondary to individual physician factors in determining successful enrollment of patients onto clinical trials... - Outpatient implantation of a central venous access system in gynecologic oncology patientsJane Shen-Gunther
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
J Reprod Med 48:875-81. 2003..To determine the feasibility, accuracy, complications and cost of implantation of the PORT-A-CATH II Fluoro-Free venous access system (SIMS Deltec Inc., St. Paul, Minnesota) in the procedure room setting... - A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?Teresa L Rutledge
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Gynecol Oncol 95:70-6. 2004..To compare stages IB1 and IB2 cervical cancers treated with radical hysterectomy (RH) and to define predictors of nodal status and recurrence... - Cervical dysplasia among women over 35 years of ageKathleen N Moore
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Am J Obstet Gynecol 199:471.e1-5. 2008..The objective of the study was to review the cytologic and histopathologic features among women 35 years of age or older with cervical dysplasia... - Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imagingNina A Mayr
Radiation Oncology Center, Department of Radiology, Oklahoma University Health Sciences Center, Oklahoma City, OK 73190, USA
Int J Radiat Oncol Biol Phys 52:14-22. 2002.... - Laparoscopic pelvic and paraaortic lymph node dissection in the obeseDennis R Scribner
Division of Gynecologic Oncology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73190, USA
Gynecol Oncol 84:426-30. 2002..The aim of this study was to determine the utility of laparoscopic pelvic and paraaortic lymph node dissection in obese women... - Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individualsJames R Hocker
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104, USA
Cancer Invest 30:189-97. 2012..These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease... - Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignanciesMichael A Gold
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Gynecol Oncol 90:325-30. 2003..To determine if amifostine could reduce the hematologic toxicity associated with topotecan... - Can frequency and severity of symptoms predict the presence of ovarian cancer?Kathleen N Moore
University of Oklahoma, HSC, Oklahoma City, OK 73104, USA
Nat Clin Pract Oncol 1:72-3. 2004 - Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancerCatherine Lhomme
Institut Gustave Roussy, Service de Gynecologie, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
J Clin Oncol 26:2674-82. 2008..To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with advanced ovarian or primary peritoneal cancer... - Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methodsSophia S Wang
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
Cancer Epidemiol Biomarkers Prev 14:2665-8. 2005..We conclude that the clear discrimination of cervical cancer risk provided by multiple test modalities is consistent with our understanding of cervical etiology related to HPV natural history... - Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytologyPhilip E Castle
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
Int J Cancer 117:1007-12. 2005.... - Ligation of an anatomic variant of renal vasculature during laparoscopic periaortic lymph node dissection: a cause of postoperative renal infarctionRam Eitan
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 91:416-20. 2003.... - Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatmentMaurie Markman
The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:988-94. 2006 - Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group studyJeffrey Bell
Ohio State University and Division of Gynecologic Oncology, Riverside Methodist Hospital Columbus Cancer Council, Columbus, OH 43214, USA
Gynecol Oncol 102:432-9. 2006.... - Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancerChristian Marth
Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
Cancer 109:645-9. 2007 - Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group StudyLari B Wenzel
College of Medicine, University of California at Irvine, Irvine, CA, USA
J Clin Oncol 25:437-43. 2007..The purpose of this report is to comprehensively evaluate the patient-reported outcomes associated with IP versus IV therapy... - Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patientsJohn K Chan
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, University of California, San Francisco Comprehensive Cancer Center, California 94143 1702, USA
Cancer 109:2454-60. 2007.... - Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong
Johns Hopkins Kimmel Cancer Center, Baltimore, USA
N Engl J Med 354:34-43. 2006..CONCLUSIONS: As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer... - Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group studyLari Wenzel
University of California, Irvine, Irvine, CA 92697, USA
Gynecol Oncol 110:60-4. 2008..To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing abdominal discomfort in patients undergoing treatment for ovarian cancer... - Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patternsSophia S Wang
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 7234, USA
Diagn Mol Pathol 14:59-64. 2005.... - Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkersMichele Follen
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:2044-51. 2003..Researchers recommended using a transgenic mouse model to test and validate new compounds, initiating vaccine and immunomodulator trials, and developing immunologic surrogate endpoint biomarkers... - A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group studyJay W Carlson
Gynecologic Oncology of West Michigan, Grand Rapids, MI 49546, USA
Gynecol Oncol 110:76-82. 2008..To evaluate VH fibrin sealant's influence on lower extremity lymphedema after inguinal lymphadenectomy in vulvar cancer patients... - Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levelsPhilip E Castle
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892 7234, USA
J Clin Immunol 22:23-7. 2002....